Us Drug Prices
- All
- News
- Videos
-
With 2024 In Mind, Joe Biden's Big Move To Lower Drug Prices
US President Joe Biden, who is campaigning for reelection with a heavy focus on easing voters' financial woes, on Tuesday launched a bid to lower the cost of certain prescription drugs -- a move Big Pharma pledged to continue battling in court.
-
Lupin Gains On Receiving US FDA Nod To Launch Drug For Onychomycosis
Lupin received approval to launch Tavaborole Topical Solution, 5 per cent in United States (US) from the United States Food and Drug Administration (FDA).
-
Cadila Healthcare Gains Over 2% After Unit Buys Drug For Menkes Disease
Cadila Healthcare said that its US subsidiary has acquired an experimental drug from Cyprium for treating Menkes disease, which is a rare recessive pediatric disease
-
Sputnik V Firm Says Its COVID-19 Vaccine Cheaper Than Pfizer, Moderna
The price per dose of the Russian coronavirus vaccine Sputnik V will be much lower than that of the vaccines of US drug giants Pfizer and Moderna, said the Russian vaccine's official Twitter account on Sunday.
-
Dr Reddy's Soars To Record High After Drug Maker Settles Patent Litigation In US
The Nifty Pharma index - which captures the performance of 10 drug makers in the country, including Dr Reddy's, Lupin, Cipla and Sun Pharma - jumped as much as 3.66 per cent.
-
Trump Says He Has Signed New Executive Order To Lower Drug Prices
US President Donald Trump said on Sunday he had signed a new executive order aimed at lowering drug prices in the United States by linking them to those of other nations.
-
US Group Raises Pricing Recommendation For Gilead's Remdesivir In COVID
Gilead Sciences Inc's antiviral remdesivir could be priced up to $5,080 per course based on benefits shown in COVID-19 patients, a U.S. drug pricing research group suggested on Wednesday, above its prior recommendation of around $4,500.
-
Cipla Shares Fall 6% After US Regulator's Warning Letter On Goa Facility
Cipla Share Price: Cipla said it will work closely with the US Food and Drug Administration (FDA) to comprehensively address all the observations.
-
Novartis Sickle-Cell Drug Gets US Approval
The drug will be priced between $84,852 and $113,136 per year for most patients, who will typically infuse themselves with between three and four vials each month, Novartis said.
-
Why Shares Of This Bengaluru-Based Drug Maker Plunged Over 8% Today
US FDA had inspected Strides Pharma's drug manufacturing facility in Puducherry from January 28 to February 5, 2019 and said that the company was caught trying to dispose quality-control records.
-
Donald Trump Promises To Reduce US Drug Prices To World's Lowest
US President Donald Trump on Friday said his administration is working on an executive order to reduce US drug prices to match the lowest in the world.
-
Lawsuit Against Aurobindo Pharma, Other Drug Makers Filed In US
Aurobindo said it does not anticipate that these matters will have a material impact on the its operations or business results.
-
Aurobindo Pharma Shares Jump 6% After Drug Maker Announces $900-Million US Acquisition
Aurobindo Pharma share price jumped more than 6 per cent in intraday trade with large volumes after the announcement. Aurobindo Pharma said it will acquire the dermatology and oral solids businesses from Sandoz Inc, USA, a unit of Swiss pharmaceutical company Novartis. Aurobindo Pharma said the deal worth $900 million was expected to close in 2019...
-
After Donald Trump Tweet, Drug Company Pfizer Reverses Price Hikes
Pfizer has reversed price increases on some drugs following White House pressure and the US drugmaker on Wednesday pledged to decide soon whether to sell its consumer drugs business.
-
Trump Says Drugmaker Pfizer Should Be "Ashamed" For Drug Price Hikes
US President Donald Trump on Monday took aim at Pfizer Inc and other US drugmakers after they raised prices on some of their medicines on July 1, saying his administration would act in response.
-
With 2024 In Mind, Joe Biden's Big Move To Lower Drug Prices
US President Joe Biden, who is campaigning for reelection with a heavy focus on easing voters' financial woes, on Tuesday launched a bid to lower the cost of certain prescription drugs -- a move Big Pharma pledged to continue battling in court.
-
Lupin Gains On Receiving US FDA Nod To Launch Drug For Onychomycosis
Lupin received approval to launch Tavaborole Topical Solution, 5 per cent in United States (US) from the United States Food and Drug Administration (FDA).
-
Cadila Healthcare Gains Over 2% After Unit Buys Drug For Menkes Disease
Cadila Healthcare said that its US subsidiary has acquired an experimental drug from Cyprium for treating Menkes disease, which is a rare recessive pediatric disease
-
Sputnik V Firm Says Its COVID-19 Vaccine Cheaper Than Pfizer, Moderna
The price per dose of the Russian coronavirus vaccine Sputnik V will be much lower than that of the vaccines of US drug giants Pfizer and Moderna, said the Russian vaccine's official Twitter account on Sunday.
-
Dr Reddy's Soars To Record High After Drug Maker Settles Patent Litigation In US
The Nifty Pharma index - which captures the performance of 10 drug makers in the country, including Dr Reddy's, Lupin, Cipla and Sun Pharma - jumped as much as 3.66 per cent.
-
Trump Says He Has Signed New Executive Order To Lower Drug Prices
US President Donald Trump said on Sunday he had signed a new executive order aimed at lowering drug prices in the United States by linking them to those of other nations.
-
US Group Raises Pricing Recommendation For Gilead's Remdesivir In COVID
Gilead Sciences Inc's antiviral remdesivir could be priced up to $5,080 per course based on benefits shown in COVID-19 patients, a U.S. drug pricing research group suggested on Wednesday, above its prior recommendation of around $4,500.
-
Cipla Shares Fall 6% After US Regulator's Warning Letter On Goa Facility
Cipla Share Price: Cipla said it will work closely with the US Food and Drug Administration (FDA) to comprehensively address all the observations.
-
Novartis Sickle-Cell Drug Gets US Approval
The drug will be priced between $84,852 and $113,136 per year for most patients, who will typically infuse themselves with between three and four vials each month, Novartis said.
-
Why Shares Of This Bengaluru-Based Drug Maker Plunged Over 8% Today
US FDA had inspected Strides Pharma's drug manufacturing facility in Puducherry from January 28 to February 5, 2019 and said that the company was caught trying to dispose quality-control records.
-
Donald Trump Promises To Reduce US Drug Prices To World's Lowest
US President Donald Trump on Friday said his administration is working on an executive order to reduce US drug prices to match the lowest in the world.
-
Lawsuit Against Aurobindo Pharma, Other Drug Makers Filed In US
Aurobindo said it does not anticipate that these matters will have a material impact on the its operations or business results.
-
Aurobindo Pharma Shares Jump 6% After Drug Maker Announces $900-Million US Acquisition
Aurobindo Pharma share price jumped more than 6 per cent in intraday trade with large volumes after the announcement. Aurobindo Pharma said it will acquire the dermatology and oral solids businesses from Sandoz Inc, USA, a unit of Swiss pharmaceutical company Novartis. Aurobindo Pharma said the deal worth $900 million was expected to close in 2019...
-
After Donald Trump Tweet, Drug Company Pfizer Reverses Price Hikes
Pfizer has reversed price increases on some drugs following White House pressure and the US drugmaker on Wednesday pledged to decide soon whether to sell its consumer drugs business.
-
Trump Says Drugmaker Pfizer Should Be "Ashamed" For Drug Price Hikes
US President Donald Trump on Monday took aim at Pfizer Inc and other US drugmakers after they raised prices on some of their medicines on July 1, saying his administration would act in response.
